I Share Price

Open 3.26 Change Price %
High 3.26 1 Day 0.04 1.25
Low 3.15 1 Week 0.00 0.00
Close 3.23 1 Month 0.00 0.00
Volume 7625 1 Year -0.73 -18.43
52 Week High 4.50
52 Week Low 2.84
I Important Levels
Resistance 2 3.33
Resistance 1 3.29
Pivot 3.21
Support 1 3.17
Support 2 3.13
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
ECA 15.09 4.43%
ECA 15.09 4.43%
ECA 15.09 4.43%
SC 60.83 -0.44%
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
PWC 0.10 25.00%
PWC 0.10 25.00%
GGA 0.06 20.00%
ANX 0.07 16.67%
ANX 0.07 16.67%
COM 2.27 14.07%
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
NXJ 2.35 -10.31%
NXJ 2.35 -10.31%
RN 0.09 -10.00%
RN 0.09 -10.00%
CTU-A 0.19 -9.52%
TNP 0.90 -9.09%
TNP 0.90 -9.09%
TNX 0.34 -8.11%
QEC 0.74 -7.50%

IntelliPharmaCeutics (TSE: I)

I Technical Analysis 1.5
As on 17th Mar 2017 I Share Price closed @ 3.23 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.94 & Sell for SHORT-TERM with Stoploss of 3.46 we also expect STOCK to react on Following IMPORTANT LEVELS.
I Target for May
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
I Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.intellipharmaceutics.com
I Address
30 Worcester Road
Toronto, ON M9W 5X2
Phone: 416-798-3001
Fax: 416-798-3007
I Latest News
Interactive Technical Analysis Chart IntelliPharmaCeutics ( I TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on IntelliPharmaCeutics
I Business Profile
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled and targeted release oral solid dosage drugs in Canada. The company has a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, such as neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. Its products under FDA review include Focalin XR, an extended release capsule for hyperactivity disorders; Effexor XR, an extended release capsule for depression; Protonix, a tablet for gastroesophageal reflux diseases; Glucophage XR, a tablet for managing type 2 diabetes; Seroquel XR, a tablet for the treatment of schizophrenia, bipolar disorders, and depressive disorders; Lamictal XR, a tablet for anti-convulsant for epilepsy; and Keppra XR, a tablet for the treatment of partial onset seizures for epilepsy, as well as Pristiq, a tablet for depression. The company is also developing Coreg CR, a capsule, which is in late-stage development for heart failure and hypertension; OxyContin, a controlled release capsule that is in phase I clinical trial for pain; and Lyrica, a capsule, which is in phase I clinical trial for neuropathic pain. Its non-generic products under development include Rexista, an oral formulation for pain relief; and Regabati XR, a pregabalin extended release capsule that has completed an initial phase I clinical trial for neuropathic pain. The company has a license and commercialization agreement with Par Pharmaceutical, Inc. for the development and commercialization of generic Focalin XR. Intellipharmaceutics International Inc. is headquartered in Toronto, Canada.